Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from CLSA Premium Ltd. ( (HK:6877) ).
Top Eminent Healthcare Group Limited has updated the terms of reference of its nomination committee, reflecting board resolutions passed on 16 March 2026 and earlier amendments in 2017 and 2018. The committee, comprising at least three directors with a majority of independent non-executive directors, is tasked with overseeing board appointments under a structured framework that aligns with Hong Kong listing rules and the company’s articles of association.
The revised terms clarify the composition, tenure, and automatic cessation of membership tied to board status, as well as the appointment of a committee chairman from the board or independent non-executive directors. They also formalize procedures for meeting frequency, quorum, notice periods, decision-making, and the role of the company secretary, aiming to reinforce governance transparency and efficiency for stakeholders.
The most recent analyst rating on (HK:6877) stock is a Hold with a HK$0.15 price target. To see the full list of analyst forecasts on CLSA Premium Ltd. stock, see the HK:6877 Stock Forecast page.
More about CLSA Premium Ltd.
Top Eminent Healthcare Group Limited is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange under stock code 6877. The group operates in the healthcare sector, with a corporate governance structure that includes a board of directors and specialized committees to oversee key functions and regulatory compliance.
Average Trading Volume: 943,061
Technical Sentiment Signal: Sell
Current Market Cap: HK$335.5M
For detailed information about 6877 stock, go to TipRanks’ Stock Analysis page.